Neuroprotection: A New Therapeutic Approach of Relapsing Remitting Multiple Sclerosis by Espinosa-Parrilla, Juan et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 13
Neuroprotection: A New Therapeutic Approach of
Relapsing Remitting Multiple Sclerosis
Juan Espinosa-Parrilla, Marco Pugliese,
Nicole Mahy and Manuel J Rodríguez
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/63730
Abstract
Neurodegenerative changes occurring early from primary acute immune-mediated
inflammation support the hypothesis that multiple sclerosis (MS) is a complex disease.
Axonal loss progresses with the disease course and represents the principal driver of
disability. In this context, the pursuit of neuroprotective therapies in multiple sclerosis
provides new valid alternatives that could significantly impact on disease progression
and neurodegenerative  changes,  including the  promotion of  restoration of  myelin
sheaths through the remyelination process. This chapter reviews promising drugs with
proposed neuroprotective or neuroregenerative effects that are currently approved or
in clinical trials for the treatment of multiple sclerosis. Although the chapter high‐
lights the diazoxide action on neuroinflammation and the results of a clinical trial with
this drug, the review also includes other molecules with oral or parenteral administra‐
tion.
Keywords: relapsing-remitting multiple sclerosis, disease-modifying drugs, neuro‐
protection, neuroregeneration, neuroinflammation, central nervous system
1. Introduction
Immunosuppressive and immunomodulatory drugs have been designed for years to treat
multiple sclerosis (MS), as it was considered the most appropriate approach to balance the
effects of the patients’ immune reaction. However, the new data recently offered by basic and
clinical research increase our understanding of this complex disease, allowing changes in its
therapeutic approach. As a consequence, the first disease-modifying drug with a suggested
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neuroprotective mechanism of action has been recently approved, broadening and improv‐
ing the therapeutic landscape against MS.
In this chapter, we review new drugs with proposed neuroprotective or neuroregenerative
effects that are currently approved or in clinical trials for MS treatment. Although we highlight
the diazoxide action on neuroinflammation and the results of a clinical trial with this drug, the
review also includes other molecules with oral or parenteral administration.
The articles analysed for this review were selected using PubMed database filtered by English
language. Clinical trials were selected at the ClinicalTrials.gov database. Studies in the
database labelled as “unknown status” were excluded. The initial search was done in Decem‐
ber 2015.
2. Treating neurodegeneration in multiple sclerosis
MS is an autoimmune disease in which elements of the neuronal myelin sheath are recognized
as antigens by the immune system. Focal inflammatory and immune actions against neuronal
cover cause a neurodegenerative process that leads to neurological impairment. The difficulty
to characterize the neurodegenerative process supports the hypothesis that MS is a complex
disease, with high variations among individuals. In any case, as a consequence of the immune
aggression, an axonal loss progresses with the disease and represents the principal driver of
disability in the chronic course of MS [1]. In this context, multiple mechanisms could contribute
to demyelination and axonal injury including energy imbalance, ion accumulation, neuroin‐
flammation and astroglial response to oxidative and metabolic stress.
2.1. Chronic neurodegenerative processes in multiple sclerosis
About 85% of MS patients present the so-called relapsing-remitting (RR) form, characterized
by unpredictable relapses related to inflammatory activity, followed by periods of months to
years of relative quietness. During the remitting period, patients present no new signs of
disease activity and, occasionally, partial remissions of symptoms associated with reparative
processes are observed [2]. Progressive forms are less frequent forms of initial MS, but about
55–65% of relapsing-remitting multiple sclerosis (RRMS) patients develop a secondary
progressive course [1].
At the pathophysiological level, the neurological impairment develops due to focal inflam‐
matory and immune attacks against the neuronal cover, which cause a chronic neurodege‐
nerative process. The reason why and where these focal demyelinating inflammatory lesions
appear within the central nervous system (CNS) remains unknown. Current hypothesis
establish that CD4-positive T lymphocytes are mainly responsible for the initial autoimmune
attack, but with a secondary role in chronic neuronal damage [3]. Resident microglia and
astrocytes, and infiltrated macrophages, B lymphocytes, natural killer (NK)-positive and CD8-
positive T cells would be the major players in the neurodegenerative process [4, 5].
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At the subcellular level, a plethora of inflammatory effectors mediating myelin and neuronal
damage have been described. These effectors include molecules such as nitric oxide (NO),
reactive oxygen species (ROS), tumour necrosis factor α (TNF-α), interferon γ (IFNγ), gran‐
zymes, perforin and matrix metalloproteinases, and also molecular processes such as activa‐
tion of the complement, antibody secretion and phagocytosis [4, 6, 7]. Furthermore, as a
concomitant event, glutamate release from damaged axons will trigger excitotoxicity, which
leads to ion imbalance and mitochondrial metabolic stress, feeding neuronal damage and
neuroinflammation [8, 9]. Thus, inflammatory damage leads to oligodendrocyte death, axon
demyelination, axonal damage, neuronal death and the formation of glial scars. Progressive
axonal injury and neuronal loss increase with the course of MS and represent the principal
driver of disability.
Key elements that mediate inflammation in MS are microglial cells. Microglia are often
considered to be macrophages of the CNS, but a series of recent findings in the mouse have
established that they are a unique cell population distinct from macrophages [10]. In normal
conditions, microglia present a surveillance state and important roles in normal development,
connectivity and plasticity of the CNS. However, they are transformed and activated by a range
of signals, such as neuronal death, mechanical injury and toxins [11]. Once activated, they form
the first line of defense against infection or injury to the CNS [12]. As a consequence, microglia
mediate and trigger a neuroinflammatory response to injury. In MS, this microglial reaction
is an early event that often precedes and triggers demyelination and neurodegeneration [13].
Figure 1. Dual role of microglia in MS. Reactive microglia mediate different pro-inflammatory (red arrows) and neuro‐
protective processes (green arrows) according to the diversity of signals from the lesioned axons and oligodendrocytes.
OG, oligodendrocytes; OP, oligodendrocyte precursors; ROS, reactive oxygen species. (Cell drawings are from SERVI‐
ER Medical Art.)
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Perivascular microglia are the antigen-presenting cells that recruit myelin-specific T cells and
promote the inflammatory process inside the CNS. This process then activates parenchymal
microglia by secreting pro-inflammatory and neurotoxic factors such as TNF-α, prostaglan‐
dins, interleukin-6 (IL-6), NO or ROS, which elicit myelin damage and neurodegeneration [11,
14]. Whether microglia adopt a phenotype that mostly exacerbates tissue injury or one that
promotes brain repair is likely to depend on the diversity of signals from the lesion environ‐
ment and the response capacity of the cell (Figure 1).
As a response to the inflammatory aggression, reparative and regenerative processes are
activated and originate MS remissions. This neuroprotective response is led by the activation
of microglia and TH2-IL-10 lymphocyte pathways, and results in inhibition of the inflamma‐
tory process, up-regulation of antioxidant mechanisms, and secretion of neurotrophic factors.
These processes promote remyelination by surviving oligodendrocytes and precursors [15–
17]. According to this, the progression of MS symptoms depends on a delicate balance between
neuroinflammation and the regenerative process. However, neuronal regeneration is not an
easy and common process within the CNS, especially for large myelinated neurons. Although
myelin sheath can be partially restored, oligodendrocytes regenerated and axons repaired, and
if the inflammatory insult persists, the degenerative damage becomes chronic and cannot be
counteracted.
According to these processes, the therapeutic approaches for MS should follow three different
but not exclusive strategies: (a) to suppress the autoimmune reaction by inhibiting the initial
immune response and lymphocyte infiltration into the CNS, (b) to prevent neurodegenerative
chronic damage by inhibiting neuroinflammation and fostering neuronal survival or (c) to
promote myelin repair and neuroregeneration.
2.2. Molecules with proposed neuroprotective and antioxidative activity
Until recently, MS pharmacotherapy has been dominated by immunomodulatory drugs,
which were developed on the basis that the disease was primarily an autoimmune disease.
This hypothesis postulates that T lymphocytes specific for myelin antigens initiate an inflam‐
matory reaction in the CNS, which ultimately leads to demyelination and subsequent neuronal
loss. However, since the approval of oral dimethyl fumarate to treat RRMS, with a proposed
antioxidative neuroprotective mechanism of action, the therapeutic landscape for MS is
rapidly evolving. Currently, the development of drugs with primarily CNS neuroprotective
effects is a pharmaceutical priority.
Pursuit of neuroprotective therapies in MS provides new valid alternatives that could
significantly impact on disease progression and neurodegenerative changes, including the
promotion of myelin sheath restoration through the remyelination process [18]. Thus, fingo‐
limod, laquinimod, Anti-LINGO antibody, (-)-epigallotechin-3-gallate (EGCG) and diazoxide
emerge as neuroprotective drugs for the treatment of MS (Table 1). Nevertheless, the neuro‐
protective effect of these compounds has not been fully established and requires further
investigation.
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Compound Proposed
mechanism
of action
Effects Clinical
phase
Key adverse
effects
Dimethyl
fumarate
Nrf2 up-regulation
Induction of IL-4-Th2
response
Anti-inflammatory
activity Decreased
lymphocyte
entry into CNSProtective
effects on oligodendrocytes,
myelin, axons and neurons
Phase III: DEFINE
and CONFIRM
Approved
Moderate infections
Elevated liver
enzymes
Leucopenia
Fingolimod Decreased expression
of S1p1 on
lymphocytes and other
cells
Decrease of T lymphocytes
infiltrated in the CNS
Anti-inflammatory and
neuroprotective microglia
phenotypes
Phase III:
TRANSFORMS and
FREEDOMS
Approved
Bradycardia and AV
block
Severe viral infections
Macular oedema
Laquinimod Unknown
Inhibition of NF-kB
activation?
Inhibition of
IL-17expression?
Decreased lymphocyte
entry into CNS
Axon protection
Decrease of pro-
inflammatory cytokines
Increased BDNF levels
Phase III studies
CONCERTO
Results expected by
2017
Elevated liver
enzymes
Infections
Anti-LINGO
antibody
BIIB033
Blockade of Nogo
signaling
promotes axonal
integrity/remyelination
functional recovery
Phase I
NCT01052506
NCT01244139
Phase II: SYNERGY
Results expected by
2016
Hypersensitivity
reactions
Elevated liver
enzymes
(−)-
Epigallotechin-3-
galeate
Inhibition of NF-kB
activation
Free radical
scavenger.
Improves muscle
metabolism during
moderate exercise in MS
patients
Phase II
SuniMS
completed. No results
available
NCT01417312
completes
Elevated liver
enzymes
(1 case)
Diazoxide Activation of KATP
channels
Maintenance of
mitochondrial
homeostasis and
function
Anti-inflammatory activity
Neuronal, axonal and
myelin protection
Modulation of antigen
presentation
Phase II:
NEUROADVAN
completed
Autoimmune
hypothyroidism (1
case)
Table 1. Neuroprotective drugs for the treatment of RRMS.
Neuroprotection: A New Therapeutic Approach of Relapsing Remitting Multiple Sclerosis
http://dx.doi.org/10.5772/63730
311
2.2.1. Dimethyl fumarate
Fumaric acid esters (FAEs) are a group of simple low-molecular structured compounds that
has been used for long time in the treatment of moderate to severe psoriasis [19]. Due to their
immunomodulatory potential, FAEs were also evaluated as a potential treatment for RRMS.
At preclinical stages, FAEs showed promising results in myelin oligodendrocyte glycoprotein
(MOG)-induced experimental autoimmune encephalomyelitis (MOG-EAE) mice, ameliorat‐
ing the disease course [20]. In vivo, the mechanism of action of dimethyl fumarate is not
completely understood. For some authors, fumarate treatment induces IL-4-producing Th2
dendritic cells [21]. In the human and mice, type II dendritic cells subsequently produce the
anti-inflammatory cytokines IL-10 and IL-4 instead of pro-inflammatory IL-12 and IL-23 [21].
This anti-inflammatory activity also causes apoptosis of activated T cells preserving the CNS
from influx of activated lymphocytes.
Regarding the neuroprotective role of fumarate, other authors found in vitro and in vivo
effects, potentially via up-regulation of the nuclear factor (erythroid-derived 2)-like 2 (Nrf2).
Dimethyl fumarate also exerts protective effects on oligodendrocytes, myelin, axons and
neurons, and reduces oxidative stress as measured by protein nitrosylation [22]. Nonetheless,
as recently shown, the protective effect of dimethyl fumarate could depend on pre-existing
tissue expression of Nrf2. Actually, Nrf2 is intrinsically higher in astrocytes and macrophages
from active MS lesions and increased Nrf2 levels have been recently reported in oligodendro‐
cytes from active MS lesions [23].
Two randomized, placebo- and active-controlled, double-blind, parallel-group Phase III
studies (DEFINE and CONFIRM) of dimethyl fumarate (Code name BG-12) have been
conducted (funded by Biogen Idec). The primary end point of these studies was the proportion
of patients who had a 2-year relapse. Secondary end points included the annualized relapse
rate (ARR), the time to confirmed progression of disability as measured by Expanded Disa‐
bility Status Scale (EDSS), and findings on brain magnetic resonance imaging scan (MRI) such
as the number of gadolinium-enhancing lesions. Both studies described highly significant
superiority of BG-12 to placebo on almost all end points in patients with RRMS [24]. In the
DEFINE and CONFIRM extension study (ENDORSE), a minimum of 5 years of treatment with
the drug was associated with continued benefit and no new/worsening tolerability signals.
Thus, in March 2013, the Food and Drug Administration (FDA) approved dimethyl fumarate
as a new first-line oral treatment for patients with RRMS. In September 2013, it was also
approved in Canada and Australia and, in 2014, the European Commission has approved the
use of the drug for the treatment of RRMS in Europe.
2.2.2. Fingolimod
Fingolimod became the first drug approved for relapsing forms of MS in the USA in 2010.
However, some safety issues were identified during the drug development process, after
completion of trials and in the first months of clinical use in the United States. These issues led
to the approval of fingolimod as a second-line drug by the European Medicines Agency (EMA)
after the FDA had licensed it as a first-line agent. In addition, contradictory results regarding
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efficacy on progression of disability in MS patients were found in the two pivotal Phase III
trials that allowed fingolimod marketing in most countries [18].
Although fingolimod was primarily believed to be a pure immunosuppressive compound,
recent findings revealed direct effects on the CNS [25]. When incorporated to the organism,
fingolimod is rapidly phosphorylated by sphingosine kinases [26] and the product of this
phosphorylation, phosphofingolimod, is a potent modulator of S1P receptors. Administration
of fingolimod and similar S1P1 modulators produce marked beneficial effects on different
animal models of MS, especially when administered preventively. The proposed mechanism
of action for fingolimod is the inhibition of encephalitogenic T-cell responses and/or their
migration into the CNS [27, 28]. According to this, EAE animals treated with fingolimod
showed a dramatic decrease of T lymphocytes infiltrated in the CNS and even a reversible
peripheral lymphocytopaenia. These animals also showed better myelin preservation and
decrease of pro-inflammatory cytokine production [29].
In the CNS, both neurons and glia profusely express S1P receptors. Some of the beneficial
effects of fingolimod in EAE and MS could be attributed to SP1 receptor modulation in these
cells and result in neuroprotection. Activation of neuronal S1P1 and S1P3 receptors promotes
neurogenesis and increases neurite outgrowth, although high and continuous activation of
neuronal S1P receptors could lead to overactivation of the glutamatergic system with delete‐
rious effects [30]. In microglia, fingolimod promotes anti-inflammatory and neuroprotective
phenotypes, but the exact mechanism of action involved remains unclear [31]. Furthermore,
one of the most discussed direct effects of fingolimod on the CNS is on myelin repair and
oligodendrocyte regeneration [32, 33].
One Phase II study, followed by an active extension, and two clinical Phase III placebo-
controlled and active comparator-controlled clinical trials (named TRANSFORMS and
FREEDOMS, sponsored by Novartis) have been performed with fingolimod in patients with
RRMS. These studies have demonstrated the efficacy of fingolimod in treating RRMS [34, 35].
More recently, FREEDOMS II, a third Phase III trial of fingolimod, was conducted predomi‐
nantly in USA and Canada. The trial replicated the findings of FREEDOMS regarding the ARR
and MRI outcomes, but the significant effect on reducing EDSS score progression was not
confirmed. On the other hand, disability showed a statistically significant change in favour of
fingolimod treatment in the FREEDOMS II study [36]. Finally, the recently completed IN‐
FORMS trial showed no significant benefit of fingolimod on neurological disability in primary
progressive MS patients treated for at least 3 years [37].
2.2.3. Laquinimod
Laquinimod (N-ethyl-N-phenyl-5-chloro-1,2-dihydroxy-1-methyl-2-oxo-quinoline-3-carbox‐
amide) is structurally related to linomide, which was tested for efficacy in MS more than one
decade ago, and discontinued after serious adverse events occurred in a Phase III trial [38,
39]. After an extensive screening of a large number of chemically modified quinoline-3-
carboxamides, laquinimod was selected to have less toxicity and better efficacy than linomide
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in various experimental autoimmune inflammatory-mediated animal models, including
experimental autoimmune neuritis in Lewis rats [40].
The precise mechanism by which laquinimod induces these beneficial effects is yet to be fully
elucidated. Preclinical studies in EAE mice have shown that laquinimod might protect myelin
and axons by decreasing pro-inflammatory cytokines such as IL-17 by T cells [41]. In addition,
suppression of the nuclear factor-kappaB (NF-κB) pathway that concordantly led to the
activation of apoptosis of immunocompetent cells was also induced by laquinimod, proving
the anti-inflammatory potency of the drug [42]. Regarding the effects in the CNS, laquinimod
treatment prevented the loss of brain-derived neurotrophic factor (BDNF) induced by the
disease process. In EAE mice, laquinimod induced an elevation of BDNF expression in various
brain regions to reach similar BDNF concentration as that of naïve controls [43]. In the human,
a Phase II study undergoing laquinimod treatment showed a significant and specific elevation
of serum BDNF levels compared to the placebo group after 3 months of treatment [44]. Whether
laquinimod directly affects BDNF expression within the neurons, or induces bystander
mechanisms that arrest the inflammatory progression and facilitates neuroprotection, needs
to be further clarified.
Two Phase III clinical trials of laquinimod in RRMS (the ALLEGRO and BRAVO trial spon‐
sored by TEVA) have been completed. In the first one, treatment with laquinimod as compared
with placebo was associated with a modest reduction in ARR, decreased the risk of disability
progression and reduced the number of gadolinium-enhancing lesions detected by MRI.
However, the failure to meet primary end point in the BRAVO study led the manufacturer to
delay requesting FDA approval. On May 2013, laquinimod was approved in Russia as a
treatment for RRMS.
Nevertheless, in 2013 Teva Pharmaceutical and Active Biotech started the third Phase III trial
of laquinimod in patients with RRMS. The study is designed to evaluate the safety and efficacy
of laquinimod with a primary end point of time to confirmed disability progression, as
measured by the EDSS (CONCERTO trial, ClinicalTrials.gov Identifier: NCT01707992).
CONCERTO results are expected to be available towards mid-2017.
2.2.4. Anti-LINGO antibody
Nogo receptor-interacting protein (LINGO-1) is a transmembrane signal-transducing mole‐
cule, selectively expressed by oligodendrocytes and neurons and that associates with the
Nogo-66 receptor (NgR1) complex [45]. NgR1 binds myelin-associated inhibitors of axonal
regeneration such as Nogo-A, myelin-associated glycoprotein and oligodendrocyte myelin
glycoprotein [46]. In response to CNS injury and demyelination, oligodendrocyte precursor
cells and stem cells from the white matter become activated, migrate to the demyelinated area,
proliferate and differentiate into oligodendrocytes that will remyelinate damaged axons. In
chronic MS lesions, despite the presence of oligodendrocyte precursors in demyelinated
plaques and the close proximity between pre-myelinating oligodendrocytes and demyelinated
axons, axonal remyelination failed. This suggests that the differentiation process may be locally
blocked by inhibitory factors [47].
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In animal models, LINGO-1 expression is up-regulated in rat spinal cord injury, experimental
EAE, 6-hydroxydopamine neurotoxic lesions and glaucoma models [48, 49]. Several works
have reported the blockade of Nogo signalling as a therapeutic approach for neurological
disorders such as spinal cord injury, traumatic brain injury, stroke, schizophrenia, amyotro‐
phic lateral sclerosis and MS [50]. Animal models provide evidence that LINGO-1 is a potent
inhibitor of axonal remyelination and regeneration in vivo. For example, transgenic mice
overexpressing full-length LINGO-1 under the neuronal promoter of synapsin showed a
significant reduction in the number of myelinated axons in the spinal cord and brain at P8 [51].
Other authors showed that neurite outgrowth inhibitor Nogo-A is involved in autoimmune-
mediated demyelination in vivo [52].
BIIB033 is a monoclonal antibody that inhibits LINGO-1 and promotes axonal integrity/
remyelination in MOG-EAE mice [49]. In preclinical experiments, LINGO-1 antagonist
antibodies did not alter EAE onset but did significantly mitigate disease severity across all
stages of disease progression. This functional recovery in EAE correlates with improved axonal
integrity as determined by magnetic resonance diffusion tensor imaging, and with newly
formed myelin sheaths as determined by electron microscopy [53].
Biogen Idec Inc. started two different human studies with BIIB033 in 2010 (ClinicalTrials.gov
Identifier: NCT01244139 and NCT01052506, respectively). Both studies finished in 2012 and
BIIB033 showed favourable safety profile, desirable pharmacokinetic in healthy adults and MS
patients and predicted brain penetration [53]. Based on these promising results, in 2013, Biogen
started a Phase II dose-response study to assess the efficacy, safety, tolerability and pharma‐
cokinetics of BIIB033 in 400 RRMS patients when used concurrently with Interferon β-1a
(Avonex®) (SYNERGY, ClinicalTrials.gov Identifier: NCT01864148). SYNERGY results are
expected to be available along 2016.
2.2.5. (−)-Epigallotechin-3-gallate
Green tea consumption has been associated to differences in the incidence of some diseases
such as different kinds of cancer or cardiovascular pathologies [54]. Its composition includes,
among other bioactive molecules, vitamins, pro-vitamins and antioxidants. Some of the more
abundant components are tea polyphenols, also known as catechins, especially the (-)-
epigallotechin-3-gallate (EGCG) [55]. EGCG has been profusely studied as an anticancer
compound, as long as it can cause apoptosis and arrest cell cycle of tumoural cells [56]. As long
as EGCG presents antioxidative properties, it can act as a chelator of neurotoxic metals and
inhibit pro-inflammatory processes [57].
Efficacy studies in the EAE models for MS have shown that, alone or in combination with
approved treatments for MS, oral EGCG ameliorated disease course and decreases EAE
severity, preventing and reversing disability. This positive effect has been mainly attributed
to the inhibition of NF-κB-mediated inflammation, cell proliferation, TNF-α secretion and Th1/
Th2 response. EGCG enhanced axonal preservation and inhibited neuronal apoptosis in
treated animals [58]. The neuroprotective profile of EGCG has been attributed to its activity
as a free radical scavenger [58]. Although this effect may be related with the inhibition of NF-
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κB pathway and glial reactivity, this indirect neuroprotection is also of main interest for the
treatment of MS and other neurodegenerative diseases.
Several epidemiologic studies and clinical trials have been performed to test the preventive
and therapeutic effects of EGCG in neurodegenerative diseases such as Alzheimer’s, Parkin‐
son’s or Huntington’s diseases [59]. In general, these studies show no EGCG-related preven‐
tion of neuronal and glial cell death in patients [59]. In 2013, a multicentric Phase II national
study to investigate the anti-inflammatory and neuroprotective effects of EGCG in 120 RRMS
patients was started (SuniMS Study, ClinicalTrials.gov identifier: NCT00525668, sponsored by
Charite University, Berlin, Germany). At the moment, no results are available for this study.
Finally, to analyse the metabolic effects of EGCG and to assess the importance of lipid oxidation
in fuel muscle’s energy metabolism and its relationship with muscle weakness and fatigue in
RRMS patients, the same institution completed a clinical research trial in 2013 (ClinicalTri‐
als.gov identifier: NCT01417312). Results showed that EGCG given to MS patients over 12
weeks improves muscle metabolism during moderate exercise to a greater extent in men than
in women, possibly because of sex-specific effects on autonomic and endocrine control. These
results indicate that EGCG could be a promising treatment for MS, with a good- and well-
known safety profile and an interesting combinability with other treatments. However, as the
EGCG pass through the blood-brain barrier in humans is still controversial, its bioavailability
remains to be characterized [60].
3. Effects of diazoxide in multiple sclerosis
3.1. KATP channels and neuroinflammation
Adenosine triphosphate (ATP)-dependent potassium (KATP) channels play important roles in
many cellular functions by coupling cell metabolism to electrical activity. First detected in
cardiac myocytes, they are also expressed in a wide number of cell types such as pancreatic
β-cells, skeletal and smooth myocytes, neurons and microglia. In these cells, KATP channels
regulate potassium fluxes across the cell membrane when glucose is available in sufficient
conditions, which couple the electrical activity of the cell to energy metabolism [61, 62]. An
increase in the cellular ATP concentration leads to channel closure and membrane depolari‐
zation. On the contrary, metabolic inhibition opens KATP channels and suppresses electrical
activity.
Functional KATP channels in the cell membrane are assembled as a heterooctameric complex
[63] from two structurally distinct subunits: the regulatory sulphonylurea receptor (SUR) and
the pore-forming inwardly rectifying potassium channel (Kir) subunit 6.1 or 6.2. While ATP
inhibits the KATP channel by directly binding to the cytoplasmic Kir6 domains, activators, such
as potassium channel openers (KCOs), and inhibitors, such as sulphonylurea drugs [64], bind
SUR to modulate the channel. Similar KATP channels have also been described in the mito‐
chondria, located on the inner membrane of these organelles where they play a crucial role in
the maintenance of mitochondrial homeostasis and function [65].
Trending Topics in Multiple Sclerosis316
In recent years, KATP channels have attracted increasing interest as targets for drug develop‐
ment. Their pivotal role in a plethora of physiological processes has been underscored by recent
discoveries linking potassium channel mutations to various diseases. The second generation
of KCOs with an improved in vitro or in vivo selectivity has broadened the chemical diversity
of KATP channel ligands. On the other hand, considering the unique role that KATP channels play
in the maintenance of cellular homeostasis, KCOs add their potential in promoting protection
against metabolic stress to the already existing pharmacotherapy. Studies in animal models
showed KCO effects in several pathological situations such as hypertension, cardiac ischaemia
or asthma, which indicates a broad therapeutic potential for KCOs. For example, in the smooth
muscle of blood vessels and pancreatic β-cells, diazoxide (7-chloro-3-methyl-4H-1,2,4-
benzothiadiazine 1,1-dioxide) binds with similar affinities to SUR1 and SUR2B subunits of
KATP channels, increases membrane permeability to potassium ions and induces hyperpolari‐
zation [64]. In these cells, diazoxide-induced hyperpolarization inhibits the opening of voltage-
gated calcium channels, and results in vasorelaxation and inhibition of insulin secretion [66].
As a consequence, diazoxide has been used since the 1970s for treating malignant hypertension
and hypoglycaemia in the United States, Canada, and most European countries [67].
Our laboratory has described the expression of KATP channels in microglia [68–70], through
which they control the release of a diversity of inflammatory mediators, such as NO, IL-6 or
TNF-α [71, 72]. We also evidenced that reactive microglia increase the expression of the KATP-
channel components Kir6.1, Kir6.2, SUR1 and SUR2B [69, 73]. With this increased microglial
expression, KCOs may modulate neuroinflammation. In this line, we and other authors have
documented that pharmacological activation of KATP channels with diazoxide can exert CNS
neuroprotective and anti-inflammatory effects against excitotoxicity, ischaemia, trauma and
neurotoxicants [71, 72, 74, 75]. For example, any rat brain microinjection of glutamate ana‐
logues triggers a persistent process that leads to progressive atrophy with a widespread
neuronal loss and a concomitant neuroinflammation [76]. This neurodegenerative process is
reduced by diazoxide oral treatment, which ameliorated microglia-mediated inflammation
and reduced neuronal loss [73].
Controlling the extent of microglial activation may offer prospective clinical therapeutic
benefits for inflammation-related neurodegenerative disorders [73]. In this context, increased
expression of KATP channels by activated microglia and the specific anti-inflammatory actions
of diazoxide reveal the use of this drug as a therapeutic agent to treat MS inflammatory
processes.
3.2. KATP channel openers and experimental autoimmune encephalomyelitis
We analysed the putative neuroprotective effects of diazoxide on an EAE murine model of MS
by its oral administration in the classical EAE MOG35-55 mouse model for preclinical studies
of MS [72]. The doses tested (0.8 and 0.05 mg/kg) were below those that induce blood glucose
increase (>1 mg/kg) and both of them ameliorated clinical signs of EAE, being 0.8 mg/kg more
effective [72]. Then, this dose was tested in two different experimental designs: (a) a preventive
paradigm, in which diazoxide was administrated daily starting on the same day animals were
immunized and (b) a palliative paradigm, in which mice were treated with diazoxide daily
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starting when they reached a clinical score of ≥1. In both cases, the treatment showed similar
effectiveness and mice treated with diazoxide obtained a lower clinical score during the chronic
phase of EAE. However, in the preventive paradigm, diazoxide could not delay EAE onset or
reduce the number of animals developing EAE. This indicates that diazoxide effects could be
mediated mainly by neuroprotection rather than by immunosuppression. The histopatholog‐
ical analysis of injured spinal cords confirmed that diazoxide elicited a significant reduction
in myelin and axonal loss accompanied by a decrease in glial activation and neuronal damage,
but it did not affect the number of infiltrating lymphocytes positive for CD3 and CD20.
We then analysed the neuroprotective properties of diazoxide in vitro and ex vivo [77]. In this
study, diazoxide effectively protected NSC-34 motoneurons against oxidative, excitotoxic and
inflammatory insults. It also enhanced the expression and nuclear translocation of Nrf2 in these
cells as well as in the spinal cord of EAE animals orally administered with diazoxide. This
demonstrated that one of the mechanisms of actions implied in the neuroprotective role of
diazoxide is mediated by the activation of Nrf2 expression and nuclear translocation. Finally,
diazoxide decreased neuronal death in organotypic hippocampal slice cultures after excito‐
toxicity and preserved myelin sheath in organotypic cerebellar cultures exposed to pro-
inflammatory demyelinating damage. Thus, diazoxide is a neuroprotective agent against
oxidative stress-induced damage and cellular dysfunction.
We finally studied the putative actions of diazoxide on autoimmune key processes during EAE
such as antigen presentation and lymphocyte activation and proliferation [78]. For this, we
analysed KATP channel expression in CD4-positive T cells and the proliferative of lymphocyte
response in the EAE model. When we used whole splenocytes to test whether diazoxide could
modulate lymphocyte proliferation, results showed a significant inhibition of the lymphocyte
proliferative rate both in vitro and in vivo. Also, the expression of dendritic cell activation
markers such as CD83, CD80, CD86 or major histocompatibility complex class II was reduced
in cultures treated with diazoxide. However, we observed no inhibition of cell proliferation
when isolated CD4-positive T lymphocytes were used instead of whole splenocytes. Diazoxide
also failed to inhibit the expression of lymphocyte activation markers. These results suggest
that although diazoxide does not directly suppress lymphocyte activation and proliferation,
it could modulate lymphocyte activity by regulating antigen presentation. These discrete
effects indicate again that diazoxide treatment attenuates EAE pathology with no immuno‐
suppressive effects.
Taken together, at the doses studied, our results demonstrate novel actions of diazoxide as an
anti-inflammatory drug that present beneficial effects on EAE through neuroprotection. At the
functional level, diazoxide is a neuroprotective agent against oxidative stress-induced damage
and cellular dysfunction (Figure 2). It attenuates EAE pathology not by causing lymphocyte
suppression but by modulating immune communication, decreasing glial harmful activation
and promoting myelin and neuronal protection. Thus, treatment with this widely used and
well-tolerated drug may be a useful therapeutic intervention in ameliorating MS disease.
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Figure 2. Diazoxide modifies microglial reactivity in brain. Drawing of the effects of diazoxide in the microglial reac‐
tion during MS. (1) Diazoxide (Dzx) binds to mitochondrial KATP channels, induces depolarization of the mitochondrial
internal membrane (MIM) and potentiates the H+ gradient generated by the electron transport chain (ETC). This en‐
hances both ATP synthesis and calcium concentration by activation of ATP synthase and the mitochondrial calcium
uniporter (MCU), respectively. Calcium in the mitochondria also increases the tricarboxylic acid cycle (TCA) flux by
activation of deshydrogenases and enhances ATP production [73]. Dzx also activates KATP channels from the plasma
membrane, which modifies the cell response to activation signals, (2) activates Nrf2 and (3) through a mechanism that
remains to be described. ARE, antioxidant response element; NE, nuclear envelope.
3.3. Effects of diazoxide in MS patients
Based on the positive preclinical studies and considering that diazoxide has been on the market
for decades with an excellent safety profile, two Spanish biotechnological companies, Neurotec
Pharma and Advancell, performed a clinical development programme to assess diazoxide
efficacy and safety in MS patients. NEUROADVAN trial (ClinicalTrials.gov identifier:
NCT01428726) was initiated in 2011 and ended in 2014. NEUROADVAN was a Phase IIa,
multinational, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety
of diazoxide. The drug was orally administered at two different doses and compared in 103
patients with RRMS versus placebo (1:1:1). The total duration of the treatment was 6 months.
Additionally, patients were allowed to continue during an optional extension period, in the
same arm of the study, in a blinded way, until study finalization.
Men and women aged 18–55 years with RRMS (McDonald criteria 2010 [79]) and an EDSS
score of 0–5.0 were eligible for the study. The inclusion criteria required at least one relapse in
the previous 2 years or the presence of at least one Gad1 lesion in the previous year. During
24 weeks, patients received one daily oral tablet with 0.3 or 4 mg diazoxide. MRI scans were
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performed at baseline and every 4 weeks until the end of the study. Patients enrolled in the
follow-up study were subjected to an additional scan at week 48.
The primary efficacy end point was that the number of new Gad1 lesions appeared on T1-
weighted sequences from weeks 4 to 24. This end point has been validated in many previous
6-month MS trials and was based on the diazoxide effects on microglia activation and blood-
brain barrier closing. Secondary MRI end points included cumulative number of lesions on
T2-weighted sequences for all MRIs, cumulative number of lesions on T2-weighted sequences
in the 6 months of the study (compared with the baseline MRI); cumulative number of
combined unique active lesions (CUALs), addition of new or enlarged lesions on T2-weighted
sequences that do not enhance with gadolinium and new Gad1 lesions for all MRIs; cumulative
number of CUALs, addition of new or enlarged lesions on T2-weighted sequences that do not
enhance with gadolinium and new Gad1 lesions in the 6 months after starting therapy
(compared with the baseline MRI); number of patients without Gad1 lesions in T1-weighted
sequences in the 6 months after starting therapy; and percentage brain volume change (PBVC).
Secondary clinical end points also included the measurement of relapse-free status, relapse
rate, number of relapses requiring corticosteroid treatment, time to first relapse during the
trial, change in EDSS scale and quality of life. Secondary safety end points were monitorized
during the 6 months of therapy up until 15 days after the last dose of diazoxide and included
incidence, nature and severity of adverse events (AEs). Control of glucose levels, glycated
haemoglobin and blood pressure were also monitorized.
The results of the clinical trial showed no differences in the diazoxide groups in the primary
end point or in the other MRI variables associated with the presence of new lesions [80].
However, an interesting decrease in the PBVC in the patients who received diazoxide com‐
pared with placebo was found. The number of new T2/Proton Density lesions converting to
black holes was not different between arms. Finally, in accordance with the small sample size
of the trial, no differences were detected in clinical variables of relapse-free status, relapse rate,
number of relapses requiring corticosteroid treatment, change in EDSS or quality of life.
There were six serious adverse events during the study but only a case with autoimmune
hypothyroidism was considered to be related to the therapy that was not discontinued.
Regarding the described clinical effects of diazoxide on glycaemia, the detected glucose blood
levels were always within the limits of normality. This confirms that the diazoxide doses used
in this trial were lower than those that induce hyperglycaemic and hypotensive effects.
As commented above, at the doses tested, diazoxide does not seem to have a significant effect
that impedes the appearance of new Gad1 lesions. However, although patients were randomly
distributed within the groups, at the beginning of the study those patients receiving diazoxide
presented a higher number of Gad1 lesions than patients included in the placebo group. This
initial higher disease activity in the group treated with diazoxide was maintained throughout
the trial. These findings confirm the need to perform an extensive and accurate selection of
patients, in terms of the activity of the disease, which must be carried out prior to the clinical
trial.
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Regarding the effects of diazoxide on brain atrophy, PBVC progressed more slowly in treated
patients in a dose-dependent manner. This is consistent with a recent study that validates the
measurement of brain atrophy as an outcome for Phase II trials in RRMS [81]. However, taking
into account that treated patients had a more active disease, and that diazoxide presents
vasodilator actions and peripheral resistance, the reduced atrophy found in patients treated
with diazoxide may also be secondary to fluid shifts and not a true protection against brain
injury. Nevertheless, the effects in slowing the progression of brain atrophy would require
further validation.
To sum up, NEUROADVAN study indicates that diazoxide is a safe drug, well tolerated in
patients with MS, but it was not possible to find evidence of efficacy in preventing the
formation of new inflammatory lesions.
4. Conclusion
Neurodegenerative changes in MS such as demyelination and axonal loss take place early in
the disease and independently from acute immuno-mediated inflammation. The reason why
these focal demyelinating inflammatory lesions appear within the CNS still needs to be
clarified, but diverse clinical presentations indicate the existence of different patterns of
inflammation and neurodegeneration. Nevertheless, the molecular mechanisms underlying
axonal damage in acute inflammation and chronic demyelination are potentially amenable to
therapy. In this context, the pursuit of neuroprotective therapies in MS should provide new
valid alternatives to significantly impact on disease progression. In this pursuit, the standard
view of neuroprotection, which has long been mostly focused on neurons, is no longer valid.
Instead, this view has been replaced by an integrative approach that recognizes the importance
of dynamic interactions between immune cells, microglia, astrocytes and neurons.
A proper evaluation of neurodegenerative aspects in MS remains difficult. Also, for all
mentioned drugs the neuroprotective effect has not been fully established. These issues could
be better understood by applying well-established and new clinical and imaging parameters
that require further preclinical and clinical investigations. Moreover, molecular characteriza‐
tion of the different MS clinical presentations must allow a pharmacogenomics classification
of patients and development of personalized therapies. In this line, promising future ap‐
proaches will combine high-throughput techniques such as proteomics and genomics to
investigate further MS neurodegenerative processes, in particular neuroinflammation.
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